News

Filter

Ipsen makes acquisition and signs R&D deal with Harvard

15-07-2013

French drugmaker Ipsen (Euronext: IPN) has acquired UK life sciences company Syntaxin for an upfront…

EuropeIpsenMergers & AcquisitionsNeurologicalPharmaceuticalSyntaxin

Ipsen and Inspiration Biopharma sell IB1001 rights to Cangene

06-02-2013

French drugmaker Ipsen (Euronext: IPN) and privately-held Inspiration Biopharmaceuticals entered into…

Cangene CorpIB1001Inspiration BiopharmaceuticalsIpsenMergers & AcquisitionsPharmaceutical

Ipsen and Inspiration Biopharma in deal with Baxter for OBI-1

24-01-2013

French drugmaker Ipsen (Euronext: IPN) and privately-held US firm Inspiration Biopharmaceuticals have…

Baxter InternationalIB1001Inspiration BiopharmaceuticalsIpsenMergers & AcquisitionsOBI-1Pharmaceutical

Ipsen sells North American rights for Apokyn to Britannia Pharma

03-11-2011

French drugmaker Ipsen (Euronext: IPN) today has sold its North American development and marketing rights…

ApokynBritannia PharmaceuticalsIpsenMergers & AcquisitionsNeurologicalPharmaceuticalSTADA Arzneimittel

Ipsen’s partner Inspiration initiates first patient in Phase III pivotal study of OBI-1 for acquired hemophilia A, triggering equity position

22-11-2010

French drugmaker Ipsen (Euronext: IPN) says that its partner, USA-based Inspiration Biopharmaceuticals,…

Inspiration BiopharmaceuticalsIpsenMergers & AcquisitionsPharmaceuticalRare diseasesResearch

Ipsen and Inspiration partner to create world leading hemophilia franchise that could be worth $1 billion

21-01-2010

French drugmaker Ipsen and California, USA-based Inspiration Biopharmaceuticals have entered into a partnership…

Antihemophilic FactorCardio-vascularCoagulation Factor VIIaIpsenLicensingMergers & AcquisitionsPharmaceuticalRecombinant

COMPANY SPOTLIGHT

Menarini

Back to top